In this study, patients with type 2 diabetes who are referred to the Iranian Diabetes Association are selected. Patients will receive supplementation or placebo for 24 weeks. At the end of the twenty-fourth week, anthropometric and blood pressure measurements are again evaluated and blood samples are taken after 12 to 14 hours of fasting. A 24-hour urine sample will be taken at the beginning and end of the study to measure the concentration of nitric oxide, creatinine, and microalbumin intake. Blood samples were taken to determine serum levels of fasting plasma glucose, hemoglobin glycosylated, insulin, serum TG, TC, LDL-c, HDL-c, thyroid tests (TSH, TT4, FT4, FT3, Anti-TPO), liver enzymes (gamma-glutamyltransferase , Alkaline phosphatase, alanine aminotransferase, aspartate amnesotransferase), Complete Blood Count (CBC). At the end, the mean of the variables in each group was compared during the study period and between the two groups.